<b>Introduction:</b> Female sexual dysfunction (FSD) is a serious problem that affects negatively the quality of life, interpersonal relationships and female self- confidence and might be a direct cause of...<b>Introduction:</b> Female sexual dysfunction (FSD) is a serious problem that affects negatively the quality of life, interpersonal relationships and female self- confidence and might be a direct cause of psychopathological disturbances. Female pattern hair loss (FPHL) is a common cosmetically disturbing condition affecting many women with social and psychological consequences. <b>Aim of the Work:</b> Assessment of the relationship between female sexual dysfunction and Female pattern hair loss in premenopausal females.<b> Methods:</b> A case-control study was carried on 47 female patients with FPHL and 43 age- matched control women without FPHL among premenopausal women attending dermatology and Andrology outpatient’s clinics, Suez Canal University hospital during the period from May 2018 to January 2019. History taking, clinical examination and hormonal investigation (Free Testosterone, Total Testosterone, and SHBG) were performed to all participants in the study. <b>Main Outcome Measures:</b> The Female Sexual Function Index (FSFI) was used to assess the key aspects of female sexual function in patients and controls. FPHL was diagnosed and graded by Ludwig’s classification. <b>Results:</b> Mean age of patients group was 30.12 ± 5.49 years, Regarding FPHL grading, 55.3%, 42.6% & 2.1% of patients were grades 1, 2 and 3 Ludwig’s classification respectively. FSD was found in 44.7% of patients while it was 44.2% in control group (P > 0.05). FSFI score in patients group was 26.40 ± 4.61 and in control group was 27.05 ± 3.12 (P > 0.05). Correlation between FSD prevalence and grade of FPHL by Ludwig’s classification was statistically insignificant. FSD was significantly compromised by increasing age and parity in patients and control groups (P < 0.05). <b>Conclusions:</b> The present study suggests that FSD was not significantly related to FPHL. Increased age and parity may have strong impact on sexual function in premenopausal women, while androgen hormones levels were not determinant factor.展开更多
Background: Hair loss in women has a various psychosocial impact and effective treatments have been required. Camouflaging products which cover exposed areas on the scalp and hide visible hair loss are common, but med...Background: Hair loss in women has a various psychosocial impact and effective treatments have been required. Camouflaging products which cover exposed areas on the scalp and hide visible hair loss are common, but medical therapies for female pattern hair loss (FPHL) are not so common. We have treated patients with FPHL using our combination therapy that consists of oral spironolactone, oral and topical minoxidil, and an injectable treatment for six years. Methods: 4568 female patients were treated between the years 2013 and 2018. Our combination therapy consists of 25 mg oral spironolactone once daily, 2.5 mg oral and 5% solution topical minoxidil twice daily, and an injectable treatment once monthly for 6 - 12 months. Digital photographs were taken pre- and post-treatment, and patient assessments were recorded after 6 and 12 months post-treatment. Results: Significant improvement was observed compared to the pre-treatment for all patients in the digital photographs. 95% and 96% of patients reported satisfaction with the results of the treatment after 6 and 12 months post-treatment, respectively. Minor complications were observed in a total of 223 (4.9%) patients, characterized by slight pain and bleeding due to injection, slight palpitation, swelling, hair growth in undesirable areas, headache, dizziness, itching. The seminor complications resolved spontaneously. No treatment-related adverse events were observed. Conclusion: A combination of these therapeutic options offers rapid and highly efficacious treatment for FPHL with minimal complications, and is recommended as an effective treatment for FPHL.展开更多
文摘<b>Introduction:</b> Female sexual dysfunction (FSD) is a serious problem that affects negatively the quality of life, interpersonal relationships and female self- confidence and might be a direct cause of psychopathological disturbances. Female pattern hair loss (FPHL) is a common cosmetically disturbing condition affecting many women with social and psychological consequences. <b>Aim of the Work:</b> Assessment of the relationship between female sexual dysfunction and Female pattern hair loss in premenopausal females.<b> Methods:</b> A case-control study was carried on 47 female patients with FPHL and 43 age- matched control women without FPHL among premenopausal women attending dermatology and Andrology outpatient’s clinics, Suez Canal University hospital during the period from May 2018 to January 2019. History taking, clinical examination and hormonal investigation (Free Testosterone, Total Testosterone, and SHBG) were performed to all participants in the study. <b>Main Outcome Measures:</b> The Female Sexual Function Index (FSFI) was used to assess the key aspects of female sexual function in patients and controls. FPHL was diagnosed and graded by Ludwig’s classification. <b>Results:</b> Mean age of patients group was 30.12 ± 5.49 years, Regarding FPHL grading, 55.3%, 42.6% & 2.1% of patients were grades 1, 2 and 3 Ludwig’s classification respectively. FSD was found in 44.7% of patients while it was 44.2% in control group (P > 0.05). FSFI score in patients group was 26.40 ± 4.61 and in control group was 27.05 ± 3.12 (P > 0.05). Correlation between FSD prevalence and grade of FPHL by Ludwig’s classification was statistically insignificant. FSD was significantly compromised by increasing age and parity in patients and control groups (P < 0.05). <b>Conclusions:</b> The present study suggests that FSD was not significantly related to FPHL. Increased age and parity may have strong impact on sexual function in premenopausal women, while androgen hormones levels were not determinant factor.
文摘Background: Hair loss in women has a various psychosocial impact and effective treatments have been required. Camouflaging products which cover exposed areas on the scalp and hide visible hair loss are common, but medical therapies for female pattern hair loss (FPHL) are not so common. We have treated patients with FPHL using our combination therapy that consists of oral spironolactone, oral and topical minoxidil, and an injectable treatment for six years. Methods: 4568 female patients were treated between the years 2013 and 2018. Our combination therapy consists of 25 mg oral spironolactone once daily, 2.5 mg oral and 5% solution topical minoxidil twice daily, and an injectable treatment once monthly for 6 - 12 months. Digital photographs were taken pre- and post-treatment, and patient assessments were recorded after 6 and 12 months post-treatment. Results: Significant improvement was observed compared to the pre-treatment for all patients in the digital photographs. 95% and 96% of patients reported satisfaction with the results of the treatment after 6 and 12 months post-treatment, respectively. Minor complications were observed in a total of 223 (4.9%) patients, characterized by slight pain and bleeding due to injection, slight palpitation, swelling, hair growth in undesirable areas, headache, dizziness, itching. The seminor complications resolved spontaneously. No treatment-related adverse events were observed. Conclusion: A combination of these therapeutic options offers rapid and highly efficacious treatment for FPHL with minimal complications, and is recommended as an effective treatment for FPHL.
